Maravai Lifesciences Holdings Inc (MRVI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Maravai Lifesciences Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 6.60 $ — 89% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -40.5% failed
- More than 10% revenue growth is expected for the coming year 7.3% failed
- Share count grows by less than 3% a year 3.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -66.4% failed
- Gross margin at 40% or higher and without meaningful erosion 18.0% failed
- Goodwill from acquisitions does not grow faster than revenue 16.8% failed
- Net debt below twice EBITDA 181 m net cash passed
- Operating cash flow covers the profits of the last three years 471 m failed
- Return on capital at 15% or higher, or up versus two years ago -0.9% failed
- Insiders hold at least 10% or are net buyers 13.9% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 10.6% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.11 | -0.17 – -0.06 | 210 | 60.9% | 8 |
| 12/31/2027 | -0.09 | -0.23 – 0.00 | 226 | 19.2% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.07 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.19 | – | 56 | -23.90 | -46.40 | -15 | -21 |
| 2025: Q1 | -0.21 | – | 47 | -27.00 | -63.90 | -9 | -15 |
| 2025: Q2 | -0.27 | – | 47 | -35.40 | -83.50 | -10 | -13 |
| 2025: Q3 | -0.18 | – | 42 | -36.20 | -61.40 | -15 | -18 |
| 2025: Q4 | -0.25 | – | 50 | -11.60 | -71.60 | -23 | -25 |
| 2026: Q1 | -0.03 | – | 66 | 40.50 | -5.70 | 9 | 4 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 124 | 16 | -18 | -0.20 | 0 | 144 | 540 |
| 2019 | 143 | 24 | -8 | -0.09 | 24 | 141 | 578 |
| 2020 | 284 | 120 | 77 | 0.80 | 152 | 89 | 1,271 |
| 2021 | 799 | 555 | 182 | 1.49 | 369 | 316 | 1,918 |
| 2022 | 883 | 574 | 220 | 1.67 | 536 | 545 | 2,282 |
| 2023 | 289 | -32 | -119 | -0.90 | 126 | 417 | 1,487 |
| 2024 | 259 | -236 | -145 | -1.05 | 7 | 325 | 1,008 |
| 2025 | 186 | -7 | -131 | -0.90 | -58 | 212 | 771 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Maravai LifeSciences Holdings, Inc., ein Life-Sciences-Unternehmen, bietet Produkte, die die Entwicklung von Arzneimitteltherapien, Impfstoffen, Zell- und Gentherapien sowie Diagnostika in Nordamerika, Europa, im Nahen Osten, in Afrika, im asiatisch-pazifischen Raum sowie in Latein- und Mittelamerika ermöglichen.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 416 |
| Headquarters | San Diego, CA |
| Address | 10770 Wateridge Circle, 92121 San Diego, United States |
| Phone | 858 546 0004 |
| Website | maravai.com |
| IPO Date | 20. Nov 2020 |
| ISIN | US56600D1072 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert Andrew Eckert M.B.A. | Chairman of the Board | 1962 |
| Bernd Brust | CEO & Director | 1967 |
| Rajesh J. Asorpota | EVP & Chief Financial Officer | 1967 |
| Kurt A. Oreshack J.D. | Executive VP, General Counsel & Secretary | 1981 |
| Christine Dolan | Executive VP & GM of Cygnus Technologies | 1968 |
| Chanfeng Zhao | Senior VP & Chief Scientific Officer | – |
| Debra Hart | Senior Director of Investor Relations | – |
| Judith A. Solecki | Senior VP & Chief Human Resources Officer | – |
| Kate E. Broderick Ph.D. | Executive Vice President | – |
| Christopher C. Benoit | Executive VP & Advisor | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.